Clinical Trials in Houston

Showing 5881-5900 of 17,885 trials

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

NCT04020185

Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)

Solid Tumor, Adult

ImmuneSensor Therapeutics Inc.40 participantsStarted Sep 2019

Scottsdale, Arizona, United States • La Jolla, California, United States • Chicago, Illinois, United States +3 more locations

COMPLETEDNA< 1 mile

Osia 2 Pediatric Expansion Study

NCT05000931

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD).Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Thus the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

Mixed Hearing LossSingle-Sided DeafnessConductive Hearing Loss

Cochlear50 participantsStarted Jan 2022

Phoenix, Arizona, United States • Palo Alto, California, United States • San Diego, California, United States +4 more locations

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Osia 2 Pediatric Expansion Study

Find Trials by Condition in Houston

Pegasys® in Patients With Myeloproliferative Diseases

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

De-Implementation of Unnecessary Surgical Antibiotic Prophylaxis in Children

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

CompARing Long terM Outcomes in Chronic Stroke Survivors Across Investigational Assessments Following a Prescribed Upper Extremity Exercise Program

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

Pragmatic Trial Examining Oxygenation Prior to Intubation

Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

SpineJack System Postmarket Registry

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness